AGIOS PHARMACEUTICALS, INC. Restricted Cash and Cash Equivalents, Noncurrent
AGIOS PHARMACEUTICALS, INC. (AGIO) had Restricted Cash and Cash Equivalents, Noncurrent of $571.00 thousand as of 2014-06-30, per its 10-Q filed 2014-08-07.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2015-02-24
- 2014-06-30: Restricted Cash and Cash Equivalents, Noncurrent $571.00K.
- 2014-03-31: Restricted Cash and Cash Equivalents, Noncurrent $571.00K.
- 2013-12-31: Restricted Cash and Cash Equivalents, Noncurrent $571.00K.
- 2013-09-30: Restricted Cash and Cash Equivalents, Noncurrent $571.00K.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2014-06-30 | $571.00K 10-Q · filed 2014-08-07 |
| 2014-03-31 | $571.00K 10-Q · filed 2014-05-09 |
| 2013-12-31 | $571.00K 10-K · filed 2015-02-24 |
| 2013-09-30 | $571.00K 10-Q · filed 2013-11-07 |
| 2013-06-30 | $571.00K 10-Q · filed 2013-09-05 |
| 2012-12-31 | $571.00K 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |